Article

Relative afferent pupillary defect a red flag in decreased visual acuity

Relative afferent pupillary defect can be clinically relevant as a red flag indicating that a decrease in visual acuity may be due to something more ominous than a refractive error or media opacity, namely a retinal or optic nerve problem.

The presence of the RAPD also helps to confirm other test abnormalities, such as a visual field defect in one eye.

For these reasons, ophthalmologists should measure RAPDs, according to Randy H. Kardon, MD, PhD.

Why measure RAPDs?

"Measuring this abnormality is one of the fastest noninvasive tests of retinal and optic nerve function," said Dr. Kardon, professor of ophthalmology and director of neuro-ophthalmology, University of Iowa, and professor of ophthalmology, Surgery Division, Veterans Administration Hospital, Iowa City. "[It] is low cost, has immediate results, and can be obtained in a variety of settings. The RAPD helps to confirm or refute abnormal [test results], such as an abnormal visual field result in one eye that may not be reliable.

"The RAPD also signifies an important red flag in the clinical evaluation of decreased vision," Dr. Kardon added. "For example, during a cataract preoperative evaluation, it could signify an unexpected underlying retina or optic nerve pathology that could affect the prognosis before the surgery is performed."

In measuring and quantifying an RAPD, always remember that magnification helps, Dr. Kardon said. Magnify the pupils with plus lenses worn by the clinician or the patient.

In addition, observe the amplitude of the initial pupil contraction.

"If the clinician tries to look at too many things during the test, the evaluation might become confusing," he said.

Finally, he advised, observe a few light swings back and forth between the eyes to estimate the average difference in pupil reactions.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.